

Andrea Antinori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8196583/publications.pdf>

Version: 2024-02-01

544
papers

27,375
citations

9264

74
h-index

9103

144
g-index

549
all docs

549
docs citations

549
times ranked

19115
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy. <i>Pathogens and Global Health</i> , 2023, 117, 181-189.	2.3	9
2	Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy "naive" adults with HIV-1 infection. <i>Aids</i> , 2022, 36, 39-48.	2.2	49
3	Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 135-142.	1.6	0
4	Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 493-502.	5.8	15
5	Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 471.	2.4	0
6	Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection. <i>Pharmaceuticals</i> , 2022, 15, 403.	3.8	2
7	Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. <i>Sexually Transmitted Infections</i> , 2022, , sextrans-2021-055289.	1.9	1
8	Epidemiology, Clinical Presentation and Treatment of Non-Hepatic Hyperammonemia in ICU COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2592.	2.4	0
9	Use of Pembrolizumab for Treatment of Progressive Multifocal Leukoencephalopathy in People Living with HIV. <i>Viruses</i> , 2022, 14, 970.	3.3	3
10	Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. <i>Vaccines</i> , 2022, 10, 817.	4.4	16
11	Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. <i>Eurosurveillance</i> , 2022, 27, .	7.0	374
12	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	5.8	8
13	A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 286.e7-286.e13.	6.0	104
14	Molecular Transmission Dynamics of Primary HIV Infections in Lazio Region, Years 2013-2020. <i>Viruses</i> , 2021, 13, 176.	3.3	4
15	Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice. <i>HIV Medicine</i> , 2021, 22, 519-525.	2.2	6
16	Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era. <i>Aids</i> , 2021, 35, 1103-1112.	2.2	15
17	Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. <i>Lancet HIV</i> , 2021, 8, e197-e205.	4.7	46
18	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. <i>Journal of Infection</i> , 2021, 82, 58-66.	3.3	44

#	ARTICLE	IF	CITATIONS
19	High Levels of TRIM5 β Are Associated with Xenophagy in HIV-1-Infected Long-Term Nonprogressors. <i>Cells</i> , 2021, 10, 1207.	4.1	6
20	Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss. <i>Scientific Reports</i> , 2021, 11, 9632.	3.3	1
21	The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series. <i>Aids</i> , 2021, 35, 2341-2346.	2.2	8
22	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ μ L. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	3.0	8
23	Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. <i>BMC Infectious Diseases</i> , 2021, 21, 557.	2.9	4
24	Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008–2018 in Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3391.	2.4	3
25	Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepalCONA Foundation Cohort Study. <i>Viruses</i> , 2021, 13, 1402.	3.3	4
26	Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3272-3279.	3.0	0
27	Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106406.	2.5	4
28	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021, 73, 50-59.	5.8	18
29	Impact of ART on dynamics of growth factors and cytokines in primary HIV infection. <i>Cytokine</i> , 2020, 125, 154839.	3.2	12
30	Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 20, 163-169.	2.2	12
31	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 681-689.	3.0	8
32	Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment of Naïve Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 310-318.	2.1	127
33	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639.	3.0	7
34	Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. <i>Journal of Clinical Virology</i> , 2020, 130, 104534.	3.1	11
35	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. <i>Viruses</i> , 2020, 12, 791.	3.3	11
36	Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. <i>Journal of Infectious Diseases</i> , 2020, 222, 1807-1815.	4.0	167

#	ARTICLE	IF	CITATIONS
37	Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1618-1622.	3.0	0
38	Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. <i>Journal of Infection</i> , 2020, 80, 536-546.	3.3	38
39	Persistent gamma delta T cell dysfunction in HCV/HIV co-infection despite direct-acting antiviral therapy-induced cure. <i>Journal of Viral Hepatitis</i> , 2020, 27, 754-756.	2.0	2
40	Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1026-1030.	3.0	20
41	Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. <i>Patient</i> , 2020, 13, 375-387.	2.7	5
42	New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). <i>Chemical Biology and Drug Design</i> , 2019, 93, 50-59.	3.2	3
43	Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery. <i>Frontiers in Immunology</i> , 2019, 10, 1886.	4.8	15
44	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3295-3304.	3.0	14
45	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4≤ 200 cells/uL (the PRADAR study). <i>PLoS ONE</i> , 2019, 14, e0222650.	2.5	11
46	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	3.0	46
47	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1363-1367.	3.0	21
48	p-Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1667-1685.	4.3	5
49	In Human Immunodeficiency Virus primary infection, early combined antiretroviral therapy reduced T cell activation but failed to restore their polyfunctionality. <i>Immunology</i> , 2019, 157, 322-330.	4.4	6
50	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts ≤ 200 cells/mm ³ and HIV-RNA >5 log ₁₀ copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2732-2741.	3.0	11
51	Vitamin D deficiency is associated with neurocognitive impairment in HIV-infected subjects. <i>Infection</i> , 2019, 47, 929-935.	4.7	6
52	Impact of genotypic susceptibility score on cART outcomes during primary HIV infection. <i>Journal of Medical Virology</i> , 2019, 91, 1891-1895.	5.0	0
53	Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2019, 6, e355-e363.	4.7	107
54	Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy. <i>Sexually Transmitted Infections</i> , 2019, 95, 619-625.	1.9	18

#	ARTICLE	IF	CITATIONS
55	Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen. <i>Antiviral Therapy</i> , 2019, 24, 321-331.	1.0	4
56	Is the rate of virological failure to cART continuing to decline in recent calendar years?. <i>Journal of Clinical Virology</i> , 2019, 116, 23-28.	3.1	11
57	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	13.7	627
58	Unawareness of HCV serostatus among persons newly diagnosed with HIV. <i>Journal of Infection and Public Health</i> , 2019, 12, 733-737.	4.1	2
59	Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. <i>Virus Genes</i> , 2019, 55, 290-297.	1.6	0
60	Establishing a hepatitis C continuum of care among HIV/hepatitis C virus coinfected individuals in EuroSIDA. <i>HIV Medicine</i> , 2019, 20, 264-273.	2.2	9
61	Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 515-519.	2.5	26
62	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. <i>Aids</i> , 2019, 33, 759-762.	2.2	19
63	Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment. <i>Aids</i> , 2019, 33, 493-502.	2.2	6
64	Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study. <i>PLoS ONE</i> , 2019, 14, e0225415.	2.5	15
65	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019, 393, 143-155.	13.7	265
66	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019, 20, 99-109.	2.2	19
67	Viro-Immunological Response of Drug-Naïve HIV-1-Infected Patients Starting a First-Line Regimen with Viraemia >500,000 Copies/ml in Clinical Practice. <i>Antiviral Therapy</i> , 2018, 23, 249-257.	1.0	10
68	3-Year Efficacy and Durability of Simplification to Single Tablet Regimens: A Comparison between Co-Formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir. <i>Antiviral Therapy</i> , 2018, 23, 139-148.	1.0	9
69	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. <i>HIV Clinical Trials</i> , 2018, 19, 52-60.	2.0	6
70	Impact of antiretroviral and tuberculosis therapies on CD4 + and CD8 + HIV/M. tuberculosis-specific T-cell in co-infected subjects. <i>Immunology Letters</i> , 2018, 198, 33-43.	2.5	21
71	IL-18 and Stem Cell Factor affect hematopoietic progenitor cells in HIV-infected patients treated during primary HIV infection. <i>Cytokine</i> , 2018, 103, 34-37.	3.2	8
72	Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. <i>HIV Medicine</i> , 2018, 19, 324-338.	2.2	4

#	ARTICLE	IF	CITATIONS
73	Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1380-1383.	2.4	4
74	Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 160-164.	3.0	2
75	Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. <i>HIV Medicine</i> , 2018, 19, 252-260.	2.2	2
76	Development and validation of an HPLC-UV method for quantification of elvitegravir and two other new antiretrovirals, dolutegravir and rilpivirine, in the plasma of HIV-positive patients. <i>Biomedical Chromatography</i> , 2018, 32, e4274.	1.7	8
77	A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. <i>Aids</i> , 2018, 32, 1431-1442.	2.2	72
78	Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials. <i>Scientific Reports</i> , 2018, 8, 5288.	3.3	11
79	Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. <i>AIDS and Behavior</i> , 2018, 22, 1573-1583.	2.7	32
80	Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence. <i>HIV Medicine</i> , 2018, 19, 18-32.	2.2	31
81	Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. <i>HIV Medicine</i> , 2018, 19, 102-117.	2.2	6
82	The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. <i>HIV Medicine</i> , 2018, 19, 90-101.	2.2	14
83	UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1073, 183-190.	2.3	34
84	Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. <i>Clinical Microbiology and Infection</i> , 2018, 24, 422-427.	6.0	12
85	THE MANAGEMENT OF GERIATRIC AND FRAIL HIV PATIENTS. A 2017 UPDATE FROM THE ITALIAN GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS AND THE DIAGNOSTIC-CLINICAL MANAGEMENT OF HIV-1 INFECTED PERSONS. <i>Journal of Frailty & Aging</i> , 2018, 8, 1-7.	1.3	9
86	Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. <i>Scientific Reports</i> , 2018, 8, 15739.	3.3	2
87	Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment-naïve, HIV-1-infected patients. <i>HIV Clinical Trials</i> , 2018, 19, 158-162.	2.0	2
88	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3460-3470.	3.0	8
89	Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 907-908.	1.1	5
90	A new procedure to analyze polymorphonuclear myeloid derived suppressor cells in cryopreserved samples cells by flow cytometry. <i>PLoS ONE</i> , 2018, 13, e0202920.	2.5	7

#	ARTICLE	IF	CITATIONS
91	Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 481-490.	2.1	1
92	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1949-1954.	3.0	17
93	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018, 19, 475-484.	2.2	13
94	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018, 46, 607-615.	4.7	7
95	Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus-coinfected patients treated with direct-acting antivirals. <i>HIV Medicine</i> , 2018, 19, 578-584.	2.2	13
96	Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2480-2484.	3.0	15
97	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1955-1964.	3.0	29
98	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , 2018, 16, 79.	5.5	24
99	Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 223.	2.9	19
100	Evolution of HIV-1 transmitted drug resistance in Italy in the 2007-2014 period: A weighted analysis. <i>Journal of Clinical Virology</i> , 2018, 106, 49-52.	3.1	8
101	Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). <i>BMC Infectious Diseases</i> , 2018, 18, 357.	2.9	42
102	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018, 18, 870.	2.9	19
103	Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. <i>Journal of Clinical Virology</i> , 2018, 104, 61-64.	3.1	19
104	Oral human Papillomavirus DNA detection in HIV-positive men: prevalence, predictors, and co-occurrence at anal site. <i>BMC Infectious Diseases</i> , 2018, 18, 25.	2.9	18
105	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 177-182.	3.0	22
106	Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?. <i>HIV Medicine</i> , 2018, 19, 42-48.	2.2	8
107	Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2018, 13, e0192627.	2.5	6
108	Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial. <i>HIV Medicine</i> , 2017, 18, 5-12.	2.2	28

#	ARTICLE	IF	CITATIONS
109	HIV-Positive Individuals on Antiretroviral Therapy and with Viral Load Suppressed in 12 Infectious Diseases Clinics in Italy: Successes and Disparities in the HIV Continuum of Care. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 575-582.	1.1	7
110	Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. <i>BMC Infectious Diseases</i> , 2017, 17, 182.	2.9	25
111	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2055-2059.	3.0	28
112	In HIV/HCV co-infected patients T regulatory and myeloid-derived suppressor cells persist after successful treatment with directly acting antivirals. <i>Journal of Hepatology</i> , 2017, 67, 422-424.	3.7	20
113	HIV-Specific CD8 T Cells Producing CCL-4 Are Associated With Worse Immune Reconstitution During Chronic Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 338-344.	2.1	12
114	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≥ 50 μ mL. <i>Infection</i> , 2017, 45, 521-528.	4.7	10
115	Self-Reported Decline in Everyday Function, Cognitive Symptoms, and Cognitive Function in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, e74-e83.	2.1	23
116	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	5.8	44
117	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017, 23, 267.e1-267.e4.	6.0	11
118	Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2837-2845.	3.0	15
119	Coformulated bicittegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2017, 390, 2073-2082.	13.7	237
120	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , 2017, 4, e486-e494.	4.7	31
121	Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2827-2837.	3.9	18
122	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15
123	Brief Report: Drop in CD4+ Counts Below 200 Cells/ μ L After Reaching (or Starting From) Values Higher than 350 Cells/ μ L in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 417-422.	2.1	2
124	Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. <i>AIDS Patient Care and STDs</i> , 2017, 31, 487-494.	2.5	7
125	Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. <i>HIV Clinical Trials</i> , 2017, 18, 141-148.	2.0	16
126	Granulocytic Myeloid-Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 575-582.	2.1	25

#	ARTICLE	IF	CITATIONS
127	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, 465-471.	2.1	4
128	Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir+Ritonavir Plus Either Raltegravir or Tenofovir+Emtricitabine. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 74, 185-192.	2.1	7
129	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017, 18, 171-180.	2.2	45
130	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients. <i>Annals of Internal Medicine</i> , 2017, 166, 9.	3.9	41
131	Virological response and resistance profile in HIV-infected patients starting darunavir-containing regimens. <i>HIV Medicine</i> , 2017, 18, 21-32.	2.2	9
132	Reference curves for CD4 cell count response to combination antiretroviral therapy in HIV-infected treatment-naïve patients. <i>HIV Medicine</i> , 2017, 18, 33-44.	2.2	16
133	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878.	3.0	17
134	Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment-naïve and experienced HIV-positive patients. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 787-797.	2.0	9
135	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. <i>PLoS ONE</i> , 2017, 12, e0186549.	2.5	29
136	Immune characterization of the HBHA-specific response in <i>Mycobacterium tuberculosis</i> -infected patients with or without HIV infection. <i>PLoS ONE</i> , 2017, 12, e0183846.	2.5	31
137	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icoha cohort. <i>PLoS ONE</i> , 2017, 12, e0177402.	2.5	15
138	Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. <i>PLoS ONE</i> , 2017, 12, e0186638.	2.5	59
139	Weight Gain: A Possible Side Effect of All Antiretrovirals. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx239.	0.9	68
140	Acute rhabdomyolysis and delayed pericardial effusion in an Italian patient with Ebola virus disease: a case report. <i>BMC Infectious Diseases</i> , 2017, 17, 597.	2.9	4
141	Evolving treatment implementation among HIV-infected pregnant women and their partners: results from a national surveillance study in Italy, 2001-2015. <i>Journal of Global Health</i> , 2017, 7, 010407.	2.7	2
142	Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw557.	3.0	62
143	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. <i>PLoS ONE</i> , 2017, 12, e0171611.	2.5	10
144	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0173893.	2.5	30

#	ARTICLE	IF	CITATIONS
145	Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. <i>PLoS ONE</i> , 2017, 12, e0187095.	2.5	14
146	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. <i>PLoS ONE</i> , 2017, 12, e0187393.	2.5	11
147	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. <i>AIDS Reviews</i> , 2017, 19, .	1.0	5
148	Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1589.	4.3	6
149	Etravirine Pharmacokinetics in HIV-Infected Pregnant Women. <i>Frontiers in Pharmacology</i> , 2016, 7, 239.	3.5	15
150	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 263-271.	2.1	39
151	European <scp>AIDS</scp> Clinical Society Standard of Care meeting on <scp>HIV</scp> and related coinfections: The Rome Statements. <i>HIV Medicine</i> , 2016, 17, 445-452.	2.2	8
152	Reduced risk of Efavirenz Discontinuation in Na ⁺ ve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen. <i>HIV Medicine</i> , 2016, 17, 385-389.	2.2	3
153	Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw512.	3.0	8
154	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw846.	5.8	8
155	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	5.8	20
156	The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 7, 1-7.	2.2	3
157	Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA. <i>Journal of Clinical Virology</i> , 2016, 82, 94-100.	3.1	35
158	Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2016, 63, 1373-1379.	5.8	25
159	Blood and urine inducible protein 10 as potential markers of disease activity. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1554-1561.	1.2	44
160	Lack of Response to <scp>HBHA</scp> in <scp>HIV</scp>-Infected Patients with Latent Tuberculosis Infection. <i>Scandinavian Journal of Immunology</i> , 2016, 84, 344-352.	2.7	23
161	Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. <i>BMC Infectious Diseases</i> , 2016, 16, 401.	2.9	6
162	High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects. <i>Medicine (United States)</i> , 2016, 95, e4434.	1.0	2

#	ARTICLE	IF	CITATIONS
163	Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression. <i>Medicine (United States)</i> , 2016, 95, e5020.	1.0	2
164	Infection-related and -unrelated malignancies, <sc>HIV</sc> and the aging population. <i>HIV Medicine</i> , 2016, 17, 590-600.	2.2	37
165	Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective. <i>Clinical Drug Investigation</i> , 2016, 36, 377-387.	2.2	5
166	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2663-2669.	3.0	10
167	Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults. <i>Aids</i> , 2016, 30, 251-259.	2.2	33
168	Host and disease factors are associated with cognitive function in European <sc>HIV</sc>-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478.	2.2	7
169	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	9.1	217
170	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1637-1642.	3.0	8
171	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 538-543.	2.1	22
172	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	3.0	4
173	Discrepancies between physician's perception of depression in HIV patients and self-reported CES-D-20 assessment: the DHIVA study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 147-159.	1.2	22
174	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1056-1062.	3.0	22
175	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	1.9	43
176	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016, 22, 288.e1-288.e8.	6.0	33
177	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016, 11, e0160761.	2.5	5
178	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. <i>PLoS ONE</i> , 2016, 11, e0156360.	2.5	0
179	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. <i>New Microbiologica</i> , 2016, 39, 93-109.	0.1	13
180	Incidence and factors associated with the risk of sexually transmitted diseases in <sc>HIV</sc>-infected people seen for care in <sc>Italy</sc>: data from the <sc>Icona</sc> foundation cohort. <i>HIV Medicine</i> , 2015, 16, 412-420.	2.2	4

#	ARTICLE	IF	CITATIONS
181	Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1. <i>Aids</i> , 2015, 29, 2534-2537.	2.2	16
182	Ebola virus disease complicated with viral interstitial pneumonia: a case report. <i>BMC Infectious Diseases</i> , 2015, 15, 432.	2.9	36
183	Liver-related death among HIV/hepatitis C virus-co-infected individuals. <i>Aids</i> , 2015, 29, 1205-1215.	2.2	46
184	Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. <i>Aids</i> , 2015, 29, 1811-1820.	2.2	29
185	Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, e147-e150.	2.1	10
186	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015, 10, e0124252.	2.5	7
187	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015, 10, e0140877.	2.5	7
188	Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy. <i>PLoS ONE</i> , 2015, 10, e0135325.	2.5	21
189	Estimating Minimum Adult HIV Prevalence: A Cross-Sectional Study to Assess the Characteristics of People Living with HIV in Italy. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 282-287.	1.1	16
190	Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study. <i>Lancet HIV</i> , 2015, 2, e540-e549.	4.7	19
191	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV</i> , 2015, 2, e98-e106.	4.7	249
192	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809.	8.4	119
193	Brain tuberculosis-associated immune reconstitution inflammatory syndrome in an HIV-positive patient: a biopsy-proven case. <i>Journal of Infection in Developing Countries</i> , 2015, 9, 536-540.	1.2	4
194	Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2935-2941.	3.9	6
195	Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial. <i>Patient</i> , 2015, 8, 257-267.	2.7	15
196	HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1865-1873.	3.0	23
197	Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database. <i>Infection</i> , 2015, 43, 339-343.	4.7	9
198	Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. <i>HIV Medicine</i> , 2015, 16, 533-543.	2.2	11

#	ARTICLE	IF	CITATIONS
199	Maraviroc 150Âmg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study. <i>Clinical Microbiology and Infection</i> , 2015, 21, 510.e1-510.e9.	6.0	19
200	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Nonâ€“AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2015, 211, 178-186.	4.0	146
201	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015, 20, .	7.0	70
202	Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort. <i>PLoS ONE</i> , 2014, 9, e89861.	2.5	3
203	Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19825.	3.0	5
204	Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting. <i>Journal of the International AIDS Society</i> , 2014, 17, 19799.	3.0	1
205	Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort. <i>Journal of the International AIDS Society</i> , 2014, 17, 19812.	3.0	17
206	Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 409.	1.9	7
207	HIV infection as a permanent, acquired risk factor for VTE. <i>Nature Reviews Cardiology</i> , 2014, 11, 321-321.	13.7	8
208	Antiretroviral treatmentâ€“based cost saving interventions may offset expenses for new patients and earlier treatment start. <i>HIV Medicine</i> , 2014, 15, 165-174.	2.2	18
209	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3085-3094.	3.0	6
210	Minimal Cognitive Impairment in UK HIV-Positive Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 120-127.	2.1	58
211	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression. <i>Aids</i> , 2014, 28, 2269-2279.	2.2	22
212	Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels. <i>Clinical Infectious Diseases</i> , 2014, 58, 1156-1164.	5.8	67
213	Delayed HIV diagnosis and initiation of antiretroviral therapy. <i>Aids</i> , 2014, 28, 2297-2306.	2.2	39
214	Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. <i>Lancet</i> , The, 2014, 383, 2222-2231.	13.7	430
215	Molecular characterization of hepatitis A outbreak in the province of Rome, Lazio region, Italy, Januaryâ€“July 2013. <i>Microbes and Infection</i> , 2014, 16, 362-366.	1.9	5
216	Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. <i>BMC Infectious Diseases</i> , 2014, 14, 79.	2.9	23

#	ARTICLE	IF	CITATIONS
217	Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group. <i>Infection</i> , 2014, 42, 61-71.	4.7	7
218	Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. <i>Journal of Infection</i> , 2014, 69, 533-545.	3.3	90
219	Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1-Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort. <i>HIV Clinical Trials</i> , 2014, 15, 151-160.	2.0	10
220	Ritonavir-boosted darunavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naïve adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. <i>Lancet, The</i> , 2014, 384, 1942-1951.	13.7	158
221	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 735-741.	3.0	16
222	Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with efavirenz or efavirenz. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1090-1097.	3.0	22
223	Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy. <i>BMC Infectious Diseases</i> , 2014, 14, 398.	2.9	13
224	Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs. <i>BMC Medical Genetics</i> , 2014, 15, 76.	2.1	20
225	Understanding HIV Compartments and Reservoirs. <i>Current HIV/AIDS Reports</i> , 2014, 11, 186-194.	3.1	66
226	An imported case of acute pulmonary coccidioidomycosis in an Italian traveller. <i>Infection</i> , 2014, 42, 921-924.	4.7	10
227	Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19589.	3.0	6
228	A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naïve Patients Starting a First-Line HAART. <i>PLoS ONE</i> , 2014, 9, e105853.	2.5	9
229	Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness. <i>New Microbiologica</i> , 2014, 37, 285-306.	0.1	0
230	HIV tropism and its relationship with transmitted resistance in naïve patients. <i>Future Virology</i> , 2013, 8, 815-820.	1.8	1
231	Left thigh phlegmon caused by <i>Nocardia farcinica</i> identified by 16S rRNA sequencing in a patient with Leprosy: a case report. <i>BMC Infectious Diseases</i> , 2013, 13, 162.	2.9	6
232	Brain localization of Kaposi's sarcoma in a patient treated by combination antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2013, 13, 600.	2.9	11
233	Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks. <i>HIV Medicine</i> , 2013, 14, 391-400.	2.2	35
234	Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. <i>HIV Medicine</i> , 2013, 14, 571-577.	2.2	7

#	ARTICLE	IF	CITATIONS
235	Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program. <i>Clinical Infectious Diseases</i> , 2013, 56, 1004-1017.	5.8	178
236	Haemolytic anaemia after oral artemether+lumefantrine treatment in a patient affected by severe imported falciparum malaria. <i>Infection</i> , 2013, 41, 863-865.	4.7	28
237	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013, 10, e1001510.	8.4	256
238	Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	4.0	7
239	Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2205-2209.	3.0	8
240	Free Light Chains and the Risk of Nonmalignant AIDS Events in HIV-Infected Patients Treated With Combination Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2013, 56, 1349-1350.	5.8	3
241	Impact of Pre-Therapy Viral Load on Virological Response to Modern First-Line Haart. <i>Antiviral Therapy</i> , 2013, 18, 867-876.	1.0	34
242	Durability of Lopinavir/ritonavir mono-therapy in individuals with viral load ≤ 50 copies/mL in the observational setting. <i>Antiviral Therapy</i> , 2013, 19, 319-324.	1.0	5
243	Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. <i>Aids</i> , 2013, 27, 769-779.	2.2	70
244	Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 339-345.	2.1	14
245	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	2.9	68
246	Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 489.	1.9	13
247	The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis. <i>BMC Infectious Diseases</i> , 2013, 13, 473.	2.9	38
248	The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing. <i>PLoS ONE</i> , 2013, 8, e53603.	2.5	14
249	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. <i>Aids</i> , 2013, 27, 803-813.	2.2	70
250	Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-7.	0.7	5
251	Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition. <i>Clinical Infectious Diseases</i> , 2012, 54, 853-861.	5.8	25
252	Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing. <i>Journal of Infectious Diseases</i> , 2012, 205, 557-567.	4.0	49

#	ARTICLE	IF	CITATIONS
253	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm ³ compared with the general population: evidence from a large European observational cohort collaboration. <i>International Journal of Epidemiology</i> , 2012, 41, 433-445.	1.9	217
254	Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 685-690.	3.0	27
255	HIV-Infected Late Presenter Patients. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-2.	0.7	7
256	Low frequency of skin reactions in a cohort of patients on raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1800-1802.	3.0	1
257	Polyclonal serum-free light chains elevation in HIV-infected patients. <i>Aids</i> , 2012, 26, 2107-2110.	2.2	11
258	Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, Tj ETQq0,0 0 rgBT/Overlock	1.1	19
259	Exposure to Abacavir and Biomarkers of Cardiovascular Disease in HIV-1-Infected Patients on Suppressive Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, e98-e101.	2.1	6
260	A Randomized Comparative 96-Week Trial of Boosted Atazanavir versus Continued Boosted Protease Inhibitor in HIV-1 Patients with Abdominal Adiposity. <i>Antiviral Therapy</i> , 2012, 17, 689-700.	1.0	13
261	Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2020-2028.	3.0	35
262	The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients. <i>Clinical Microbiology and Infection</i> , 2012, 18, E289-E298.	6.0	18
263	Monophyletic outbreak of Hepatitis A involving HIV-infected men who have sex with men, Rome, Italy 2008-2009. <i>Journal of Clinical Virology</i> , 2012, 54, 26-29.	3.1	44
264	HIV incidence estimate combining HIV/AIDS surveillance, testing history information and HIV test to identify recent infections in Lazio, Italy. <i>BMC Infectious Diseases</i> , 2012, 12, 65.	2.9	14
265	The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: Results from a prospective study. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 348-353.	5.6	20
266	Beyond Virological Suppression: The Role of Adherence in the Late Haart Era. <i>Antiviral Therapy</i> , 2012, 17, 785-792.	1.0	33
267	Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. <i>American Journal of Hematology</i> , 2012, 87, 749-753.	4.1	24
268	Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. <i>BMC Health Services Research</i> , 2012, 12, 38.	2.2	0
269	Efficacy of 1998 Vs 2006 First-Line Antiretroviral Regimens for HIV Infection: An Ordinary Clinics Retrospective Investigation. <i>Journal of Antivirals & Antiretrovirals</i> , 2012, 04, .	0.1	1
270	Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. <i>New Microbiologica</i> , 2012, 35, 17-25.	0.1	19

#	ARTICLE	IF	CITATIONS
271	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012, 35, 113-59.	0.1	25
272	The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. <i>New Microbiologica</i> , 2012, 35, 259-77.	0.1	5
273	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	9.1	345
274	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. <i>PLoS ONE</i> , 2011, 6, e26009.	2.5	16
275	Interpretation of Genotypic HIV-1 Resistance to Darunavir and Virological Response: Validation of Available Systems and of a New Score. <i>Antiviral Therapy</i> , 2011, 16, 489-497.	1.0	10
276	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. <i>Aids</i> , 2011, 25, 1385-1394.	2.2	155
277	Identification and Structural Characterization of Novel Genetic Elements in the HIV-1 V3 Loop Regulating Coreceptor Usage. <i>Antiviral Therapy</i> , 2011, 16, 1035-1045.	1.0	23
278	Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome. <i>Antiviral Therapy</i> , 2011, 16, 1103-1112.	1.0	45
279	Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure*. <i>HIV Medicine</i> , 2011, 12, 4-13.	2.2	32
280	Late presentation of HIV infection: a consensus definition. <i>HIV Medicine</i> , 2011, 12, 61-64.	2.2	378
281	Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008. <i>HIV Medicine</i> , 2011, 12, 174-182.	2.2	5
282	'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2615-2623.	3.0	14
283	Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. <i>BMC Infectious Diseases</i> , 2011, 11, 23.	2.9	5
284	Prevalence of Hypovitaminosis D and Factors Associated With Vitamin D Deficiency and Morbidity Among HIV-Infected Patients Enrolled in a Large Italian Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 163-172.	2.1	59
285	Timed Short Messaging Service Improves Adherence and Virological Outcomes in HIV-1-Infected Patients With Suboptimal Adherence to Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, e113-e115.	2.1	24
286	HIV-ASSOCIATED VENOUS THROMBOEMBOLISM. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011030.	1.3	131
287	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	3.8	42
288	Is There Any Potential for First-Line Etravirine Use? Analysis From a Large Data Set of Antiretroviral Therapy-Naïve HIV-Infected Patients Undergoing Resistance Test. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 150-151.	2.1	0

#	ARTICLE	IF	CITATIONS
289	Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients. <i>Antiviral Therapy</i> , 2010, 15, 377-390.	1.0	20
290	Management of Late-presenting Patients with HIV Infection. <i>Antiviral Therapy</i> , 2010, 15, 25-30.	1.0	22
291	Introduction to Late Presentation for HIV Treatment in Europe. <i>Antiviral Therapy</i> , 2010, 15, 1-2.	1.0	10
292	Predicting the magnitude of short-term CD4 ⁺ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 165-175.	1.0	16
293	Italian consensus statement on paediatric HIV infection. <i>Infection</i> , 2010, 38, 301-319.	4.7	8
294	Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. <i>HIV Medicine</i> , 2010, 11, 104-113.	2.2	85
295	Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). <i>HIV Medicine</i> , 2010, 11, 530-4.	2.2	7
296	One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. <i>Patient Preference and Adherence</i> , 2010, 4, 115.	1.8	130
297	Incidence of Malignancies in HIV-infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study. <i>Clinical Infectious Diseases</i> , 2010, 50, 1316-1321.	5.8	56
298	Rate of CD4 ⁺ Cell Count Increase over Periods of Viral Load Suppression: Relationship with the Number of Previous Virological Failures. <i>Clinical Infectious Diseases</i> , 2010, 51, 456-464.	5.8	21
299	Patient With HIV-Associated Plasmablastic Lymphoma Responding to Bortezomib Alone and in Combination With Dexamethasone, Gemcitabine, Oxaliplatin, Cytarabine, and Pegfilgrastim Chemotherapy and Lenalidomide Alone. <i>Journal of Clinical Oncology</i> , 2010, 28, e704-e708.	1.6	89
300	Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 336-344.	2.1	32
301	Early-Stage Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 363, 2267-2267.	27.0	7
302	Death rates in HIV-positive antiretroviral-naïve patients with CD4 count greater than 350 cells per $\hat{1}/4$ L in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , 2010, 376, 340-345.	13.7	82
303	Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naïve to integrase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2305-2318.	3.0	57
304	Lopinavir/ritonavir + tenofovir Dual Therapy versus Lopinavir/ritonavir-Based Triple Therapy in HIV-Infected Antiretroviral Naïve Subjects: The Kalead Study. <i>Journal of Antivirals & Antiretrovirals</i> , 2010, 02, .	0.1	21
305	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010, 33, 195-206.	0.1	35
306	Changes in Cognition During Antiretroviral Therapy: Comparison of 2 Different Ranking Systems to Measure Antiretroviral Drug Efficacy on HIV-Associated Neurocognitive Disorders. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 56-63.	2.1	155

#	ARTICLE	IF	CITATIONS
307	Increasing Clinical Virulence in Two Decades of the Italian HIV Epidemic. <i>PLoS Pathogens</i> , 2009, 5, e1000454.	4.7	33
308	Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations in the Human Immunodeficiency Virus Type 1 Regulatory Protein. <i>Rev. Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2816-2823.	3.2	18
309	Risk of Developing Specific AIDS-Defining Illnesses in Patients Coinfected with HIV and Hepatitis C Virus With or Without Liver Cirrhosis. <i>Clinical Infectious Diseases</i> , 2009, 49, 612-622.	5.8	53
310	Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal. <i>Clinical Infectious Diseases</i> , 2009, 48, 1138-1151.	5.8	108
311	Hyperbilirubinemia during Atazanavir Treatment in 2,404 Patients in the Italian Atazanavir Expanded Access Program and MASTER Cohorts. <i>Infection</i> , 2009, 37, 244-249.	4.7	46
312	Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients. <i>Infection</i> , 2009, 37, 233-243.	4.7	9
313	Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease Naïve to Antiretroviral Therapy. <i>Infection</i> , 2009, 37, 270-82.	4.7	7
314	Effect of Suppressing HIV Viremia on the HIV Progression of Patients Undergoing a Genotype Resistance Test after Treatment Failure. <i>Infection</i> , 2009, 37, 203-209.	4.7	3
315	AIDS-related intestinal cryptosporidiosis: role of nutritional support. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2009, 1, 193-196.	0.5	0
316	Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. <i>Vaccine</i> , 2009, 27, 3306-3312.	3.8	59
317	The preventive phase I trial with the HIV-1 Tat-based vaccine. <i>Vaccine</i> , 2009, 28, 371-378.	3.8	56
318	Dynamics of NRTI Resistance Mutations during Therapy Interruption. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 57-64.	1.1	11
319	Parallel Conduction of the Phase I Preventive and Therapeutic Trials Based on the Tat Vaccine Candidate. <i>Reviews on Recent Clinical Trials</i> , 2009, 4, 195-204.	0.8	36
320	EBV and HIV-Related Lymphoma. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009032.	1.3	57
321	Characterization and structural analysis of HIV-1 integrase conservation. <i>AIDS Reviews</i> , 2009, 11, 17-29.	1.0	118
322	Historical resistance profile helps to predict salvage failure. <i>Antiviral Therapy</i> , 2009, 14, 285-291.	1.0	18
323	Evidence of Dual Sexual Transmission of Multi-resistant HIV with Two Years Persistence of Resistance to NRTI and NNRTI: a Case Report. <i>Infection</i> , 2008, 36, 178-180.	4.7	2
324	Evolution of Antiretroviral Prescription and Response over a Period of 8 years: an Italian Multicentre Observational Prospective Cohort Study. <i>Infection</i> , 2008, 36, 244-249.	4.7	10

#	ARTICLE	IF	CITATIONS
325	Recruitment criteria for acute disseminated encephalomyelitis studies: the need for consensus. <i>Neurological Sciences</i> , 2008, 29, 203-204.	1.9	9
326	Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. <i>Annals of Neurology</i> , 2008, 63, 213-221.	5.3	167
327	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , 2008, 22, 2143-2153.	2.2	207
328	Self-Reported Sexual Dysfunction Is Frequent Among HIV-Infected Persons and Is Associated with Suboptimal Adherence to Antiretrovirals. <i>AIDS Patient Care and STDs</i> , 2008, 22, 291-299.	2.5	33
329	Plasma HIV RNA Decline and Emergence of Drug Resistance Mutations among Patients with Multiple Virologic Failures Receiving Resistance Testing-Guided HAART. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 787-796.	1.1	6
330	Specific Enfuvirtide-Associated Mutational Pathways in HIV Gp41 Are Significantly Correlated With an Increase in CD4+Cell Count, Despite Virological Failure. <i>Journal of Infectious Diseases</i> , 2008, 197, 1408-1418.	4.0	38
331	Viro-Immunologic Response to Ritonavir-Boosted or Unboosted Atazanavir in a Large Cohort of Multiply Treated Patients: The CARE Study. <i>AIDS Patient Care and STDs</i> , 2008, 22, 7-16.	2.5	18
332	Progressive Multifocal Leukoencephalopathy in HIV-Infected Patients in the Era of HAART: Radiological Features at Diagnosis and Follow-Up and Correlation with Clinical Variables. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 155-162.	1.1	17
333	Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. <i>Aids</i> , 2008, 22, 1759-1767.	2.2	141
334	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , 2008, 22, 2461-2469.	2.2	51
335	gp41 Sequence Variability in HIV Type 1 Non-B Subtypes Infected Patients Undergoing Enfuvirtide Pressure. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1296-1302.	1.1	8
336	Improved Interpretation of Genotypic Changes in the HIV Reverse Transcriptase Coding Region That Determine the Virological Response to Didanosine. <i>Journal of Infectious Diseases</i> , 2007, 196, 1645-1653.	4.0	16
337	Is the CD4 Cell Percentage a Better Marker of Immunosuppression than the Absolute CD4 Cell Count in HIV-Infected Patients with Cirrhosis?. <i>Clinical Infectious Diseases</i> , 2007, 45, 650-653.	5.8	11
338	Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors. <i>Journal of Virology</i> , 2007, 81, 11507-11519.	3.4	62
339	CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1141-1147.	3.0	4
340	Continuous evidence of fast HIV disease progression related to class-wide resistance to antiretroviral drugs: a 6 year follow-up analysis of a large observational database. <i>Aids</i> , 2007, 21, 1824-1826.	2.2	10
341	Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 607-615.	2.1	47
342	Persistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 174-182.	2.1	298

#	ARTICLE	IF	CITATIONS
343	Optimal Timing and Best Antiretroviral Regimen in Treatment-naïve HIV-Infected Individuals with Advanced Disease. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 46, S9-S18.	2.1	35
344	Sexual dysfunction in HIV infection. <i>Lancet</i> , The, 2007, 369, 905-906.	13.7	19
345	Updated research nosology for HIV-associated neurocognitive disorders. <i>Neurology</i> , 2007, 69, 1789-1799.	1.1	2,277
346	Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. <i>Addiction</i> , 2007, 102, 423-431.	3.3	35
347	First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006). <i>Infection</i> , 2007, 35, 134-142.	4.7	14
348	Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. <i>Infection</i> , 2007, 35, 451-456.	4.7	3
349	The V118I Mutation as a Marker of Advanced HIV Infection and Disease Progression. <i>Antiviral Therapy</i> , 2007, 12, 163-168.	1.0	12
350	Virological response to Salvage Therapy in HIV-Infected Persons Carrying the Reverse Transcriptase K65R Mutation. <i>Antiviral Therapy</i> , 2007, 12, 1175-1184.	1.0	22
351	Neuroactive Antiretroviral Drugs Do Not Influence Neurocognitive Performance in Less Advanced HIV-Infected Patients Responding to Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 41, 332-337.	2.1	58
352	Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir. <i>Journal of Medical Virology</i> , 2006, 78, 535-541.	5.0	14
353	Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 1055-1064.	3.0	7
354	Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 714-722.	3.0	80
355	Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1103-1110.	3.3	44
356	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 2006, 166, 1632.	3.8	1,004
357	Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors. <i>Journal of Virology</i> , 2006, 80, 7186-7198.	3.4	64
358	Highly Active Antiretroviral Therapy Reduces the Age-Associated Risk of Dementia in a Cohort of Older HIV-1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 386-392.	1.1	37
359	Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. <i>Antiviral Therapy</i> , 2006, 11, 553-60.	1.0	12
360	Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison. <i>Antiviral Therapy</i> , 2006, 11, 609-18.	1.0	7

#	ARTICLE	IF	CITATIONS
361	Drug-Class-Wide Resistance to Antiretrovirals in HIV-Infected Patients Failing Therapy: Prevalence, Risk Factors and Virological Outcome. <i>Antiviral Therapy</i> , 2006, 11, 553-560.	1.0	45
362	Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison. <i>Antiviral Therapy</i> , 2006, 11, 609-618.	1.0	19
363	The Effect of HIV-1 Resistance Mutations after First-Line Virological Failure on the Possibility to Sequence Antiretroviral Drugs in Second-Line Regimens. <i>Antiviral Therapy</i> , 2006, 11, 923-930.	1.0	7
364	Structured treatment interruption in HIV-infected patients failing on multidrug therapy: is there a future for this strategy?. <i>Aids</i> , 2005, 19, 1691-1694.	2.2	5
365	Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. <i>Aids</i> , 2005, 19, 1081-1089.	2.2	116
366	Lipodystrophy Is Associated With a Low Rate of Treatment Failure in HIV-Positive Patients Switched to Atazanavir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 125-126.	2.1	1
367	Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders. <i>Infection, Genetics and Evolution</i> , 2005, 5, 247-253.	2.3	18
368	Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2005, 11, 219-224.	2.1	20
369	Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort. <i>Journal of NeuroVirology</i> , 2005, 11, 265-273.	2.1	117
370	Cell death mechanisms in HIV-associated dementia: the involvement of syncytia. <i>Cell Death and Differentiation</i> , 2005, 12, 855-858.	11.2	18
371	Investigation on the role of cell transcriptional factor Sp1 and HIV-1 TAT protein in PML onset or development. <i>Journal of Cellular Physiology</i> , 2005, 204, 913-918.	4.1	24
372	Experience with brain biopsy in acquired immune deficiency syndrome-related focal lesions of the central nervous system. <i>British Journal of Surgery</i> , 2005, 81, 1508-1511.	0.3	38
373	Acute megakaryoblastic leukemia in a patient receiving HAART. <i>American Journal of Hematology</i> , 2005, 80, 89-90.	4.1	1
374	<i>Yersinia pseudotuberculosis</i> Septicemia and HIV. <i>Emerging Infectious Diseases</i> , 2005, 11, 112-1130.	4.3	14
375	Changing pattern of primary cerebral lymphoma in the highly active antiretroviral therapy era. <i>Journal of NeuroVirology</i> , 2005, 11, 38-44.	2.1	18
376	Efficacy of Cerebrospinal Fluid (CSF)-Penetrating Antiretroviral Drugs against HIV in the Neurological Compartment: Different Patterns of Phenotypic Resistance in CSF and Plasma. <i>Clinical Infectious Diseases</i> , 2005, 41, 1787-1793.	5.8	106
377	Human immunodeficiency virus infection and acquired immunodeficiency syndrome dementia complex: Role of cells of monocyte-macrophage lineage. <i>Journal of NeuroVirology</i> , 2005, 11, 58-66.	2.1	14
378	A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted Regimens (RADAR) Study. <i>Clinical Infectious Diseases</i> , 2005, 40, 1828-1836.	5.8	49

#	ARTICLE	IF	CITATIONS
379	Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 190-195.	3.0	35
380	Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2015-2025.	3.2	58
381	Neurocognitive Impairment and Survival in a Cohort of HIV-Infected Patients Treated with HAART. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 706-713.	1.1	104
382	High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations. <i>Journal of Virology</i> , 2005, 79, 10718-10729.	3.4	50
383	Possible Child-to-Mother Transmission of HIV by Breastfeeding. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2297.	7.4	6
384	Economic evaluation of HIV treatments: The I.CO.N.A. cohort study. <i>Health Policy</i> , 2005, 74, 304-313.	3.0	13
385	Characterization of Cell Death Pathways in Human Immunodeficiency Virus-Associated Encephalitis. <i>American Journal of Pathology</i> , 2005, 167, 695-704.	3.8	33
386	Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users?. <i>Digestive and Liver Disease</i> , 2005, 38, 119-24.	0.9	22
387	Neurological complications of HIV infection and AIDS: Current and future perspectives. <i>Journal of NeuroVirology</i> , 2005, 11, 1-5.	2.1	5
388	CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 10 ⁶ cells/l. <i>Aids</i> , 2005, 19, 287-94.	2.2	24
389	Early Virological Failure after Tenofovir + Didanosine + Efavirenz Combination in HIV-Positive Patients upon Starting Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2005, 10, 505-513.	1.0	21
390	Cerebrospinal Fluid HIV-1 Infection Usually Responds Well to Antiretroviral Treatment. <i>Antiviral Therapy</i> , 2005, 10, 701-707.	1.0	44
391	The Challenge of Antiretroviral-Drug-Resistant HIV: Is There Any Possible Clinical Advantage?. <i>Current HIV Research</i> , 2004, 2, 283-292.	0.5	10
392	Positive Predictive Value of Epstein-Barr Virus DNA Detection in HIV-Related Primary Central Nervous System Lymphoma. <i>Clinical Infectious Diseases</i> , 2004, 39, 1396-1397.	5.8	10
393	Reduced Value of Thallium-201 Single-Photon Emission Computed Tomography in the Management of HIV-Related Focal Brain Lesions in the Era of Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 584-588.	1.1	19
394	Short Communication: <i>Yersinia pseudotuberculosis</i> Septicemia in an HIV-Infected Patient Failed HAART. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 709-710.	1.1	4
395	Mutations in HIV-1 Reverse Transcriptase Potentially Associated with Hypersusceptibility to Nonnucleoside Reverse Transcriptase Inhibitors: Effect on Response to Efavirenz-Based Therapy in an Urban Observational Cohort. <i>Journal of Infectious Diseases</i> , 2004, 189, 1688-1695.	4.0	27
396	Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study. <i>Clinical Infectious Diseases</i> , 2004, 38, 565-571.	5.8	118

#	ARTICLE	IF	CITATIONS
397	Q151MêMediated Multinucleoside Resistance: Prevalence, Risk Factors, and Response to Salvage Therapy. <i>Clinical Infectious Diseases</i> , 2004, 38, 433-437.	5.8	24
398	Changes in regular condom use among immigrant transsexuals attending a counselling and testing reference site in central Rome: a 12 year study. <i>Sexually Transmitted Infections</i> , 2004, 80, 541-545.	1.9	15
399	Peripheral T Cell Lymphoma with Cytotoxic Phenotype: An Emerging Disease in HIV-Infected Patients?. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 129-133.	1.1	14
400	Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. <i>International Journal of STD and AIDS</i> , 2004, 15, 254-259.	1.1	84
401	Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. <i>HIV Medicine</i> , 2004, 5, 437-447.	2.2	52
402	Patient-reported and physician-estimated adherence to HAART. <i>Journal of General Internal Medicine</i> , 2004, 19, 1104-1110.	2.6	60
403	Prevalence, Associated Factors, and Prognostic Determinants of AIDSêRelated Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1681-1691.	5.8	131
404	Depressive Symptoms, Neurocognitive Impairment, and Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Persons. <i>Psychosomatics</i> , 2004, 45, 394-402.	2.5	231
405	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	13.7	303
406	Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. <i>Aids</i> , 2004, 18, 11-19.	2.2	52
407	Selection of Antiretroviral Therapy Guided by Genotypic or Phenotypic Resistance Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1587-1598.	2.1	18
408	Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. <i>Antiviral Therapy</i> , 2004, 9, 291-6.	1.0	11
409	Construction, Training and Clinical Validation of An Interpretation System for Genotypic HIV-1 Drug Resistance Based on Fuzzy Rules Revised by Virological Outcomes. <i>Antiviral Therapy</i> , 2004, 9, 583-593.	1.0	12
410	Relative Prognostic Value of Self-Reported Adherence and Plasma Nnrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart. <i>Antiviral Therapy</i> , 2004, 9, 291-296.	1.0	32
411	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003, 9, 47-53.	2.1	157
412	Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. <i>HIV Medicine</i> , 2003, 4, 255-262.	2.2	181
413	AIDS-Related Kaposiê™s Sarcoma: Evaluation of Potential New Prognostic Factors and Assessment of the AIDS Clinical Trial Group Staging System in the Haart Eraê”the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients NaÁve From Antiretrovirals. <i>Journal of Clinical Oncology</i> , 2003, 21, 2876-2882.	1.6	150
414	B Cell Clonality in Multiple Localizations of Primary Central Nervous System Lymphomas in AIDS Patients. <i>Leukemia and Lymphoma</i> , 2003, 44, 963-966.	1.3	6

#	ARTICLE	IF	CITATIONS
415	Clinical implications of HIV-1 drug resistance in the neurological compartment. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 41-44.	1.5	25
416	Interpretation systems for genotypic drug resistance of HIV-1. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 29-34.	1.5	11
417	Discontinuation of Secondary Prophylaxis for <i>Pneumocystis carinii</i> Pneumonia in Human Immunodeficiency Virus-Infected Patients: A Randomized Trial by the CIOP Study Group. <i>Clinical Infectious Diseases</i> , 2003, 36, 645-651.	5.8	39
418	HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 37-40.	1.5	1
419	Variable Prediction of Antiretroviral Treatment Outcome by Different Systems for Interpreting Genotypic Human Immunodeficiency Virus Type 1 Drug Resistance. <i>Journal of Infectious Diseases</i> , 2003, 187, 1934-1943.	4.0	96
420	HIV Type 1 Replication in Cerebrospinal Fluid of Patients with AIDS-Related Non-Hodgkin's Lymphoma Receiving Chemotherapy and Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1091-1095.	1.1	2
421	Neurocognitive Performance and Quality of Life in Patients with HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 643-652.	1.1	107
422	Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity. <i>Neurology</i> , 2003, 61, 723-724.	1.1	11
423	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2003, 349, 1993-2003.	27.0	1,560
424	Morphologic Alterations in HIV-Infected People with Lipodystrophy Are Associated with Good Adherence to HAART. <i>HIV Clinical Trials</i> , 2003, 4, 99-106.	2.0	38
425	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003, 9, 47-53.	2.1	12
426	Dynamics of viral load rebound in plasma and semen after stopping effective antiretroviral therapy. <i>Aids</i> , 2003, 17, 1089-1092.	2.2	12
427	Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. <i>Aids</i> , 2003, 17, 1099-1102.	2.2	58
428	The Effect of Number of Mutations and of Drug-Class Sparing on Virological Response to Salvage Genotype-Guided Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2003, 8, 611-616.	1.0	9
429	Using a Database of HIV Patients Undergoing Genotypic Resistance Test after Haart Failure to Understand the Dynamics of M184V Mutation. <i>Antiviral Therapy</i> , 2003, 8, 51-56.	1.0	23
430	Virologic and Immunologic Response to Regimens Containing Nevirapine or Efavirenz in Combination with 2 Nucleoside Analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study. <i>Journal of Infectious Diseases</i> , 2002, 185, 1062-1069.	4.0	88
431	Cross-Resistance among Nonnucleoside Reverse Transcriptase Inhibitors Limits Recycling Efavirenz after Nevirapine Failure. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 835-838.	1.1	117
432	Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus-Infected Patients with Very Low CD4 Cell Counts. <i>Journal of Infectious Diseases</i> , 2002, 186, 189-197.	4.0	52

#	ARTICLE	IF	CITATIONS
433	Depression Is a Risk Factor for Suboptimal Adherence to Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S136-S139.	2.1	238
434	Underevaluation of HIV-1 Plasma Viral Load by a Commercially Available Assay in a Cluster of Patients Infected With HIV-1 A/G Circulating Recombinant Form (CRF02). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, 488-494.	2.1	26
435	Coinfection With Hepatitis Viruses and Outcome of Initial Antiretroviral Regimens in Previously Naive HIV-Infected Subjects. <i>Archives of Internal Medicine</i> , 2002, 162, 2125.	3.8	207
436	Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S123-S127.	2.1	390
437	Physician Estimates of Adherence and the Patient-Physician Relationship as a Setting to Improve Adherence to Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S158-S162.	2.1	55
438	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). <i>Aids</i> , 2002, 16, 369-379.	2.2	189
439	Adherence to Antiretroviral Therapy: Where Are We, and Where Do We Go From Here?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S95-S97.	2.1	18
440	Virologic Correlates of Adherence to Antiretroviral Medications and Therapeutic Failure. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S118-S122.	2.1	50
441	Treatment-Related Factors and Highly Active Antiretroviral Therapy Adherence. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S128-S131.	2.1	65
442	Relationship Between HAART Adherence and Adipose Tissue Alterations. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, S140-S144.	2.1	155
443	Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. <i>Aids</i> , 2002, 16, 1867-1876.	2.2	59
444	Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. <i>Blood</i> , 2002, 100, 1984-1988.	1.4	156
445	Characterization of Epstein-Barr Virus Genotype in AIDS-Related Non-Hodgkin's Lymphoma. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 19-26.	1.1	16
446	Monophyletic HIV Type 1 CRF02-AG in a Nosocomial Outbreak in Benghazi, Libya. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 727-732.	1.1	31
447	Factors Related to Virologic Failure among HIV-Positive Injecting Drug Users Treated with Combination Antiretroviral Therapy Including Two Nucleoside Reverse Transcriptase Inhibitors and Nevirapine. <i>AIDS Patient Care and STDs</i> , 2002, 16, 67-73.	2.5	31
448	Incidence of Adipose Tissue Alterations in First-Line Antiretroviral Therapy. <i>Archives of Internal Medicine</i> , 2002, 162, 2621.	3.8	66
449	Highly active antiretroviral therapy and allogeneic CD34+ peripheral blood progenitor cells transplantation in an HIV/HCV coinfecting patient with acute myeloid leukemia. <i>Experimental Hematology</i> , 2002, 30, 279-284.	0.4	36
450	Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeurolCONA study. <i>Acta Psychiatrica Scandinavica</i> , 2002, 106, 20-26.	4.5	57

#	ARTICLE	IF	CITATIONS
451	Reduction of HIV-1 viral load in saliva by indinavir-containing antiretroviral regimen. <i>Aids</i> , 2002, 16, 503-504.	2.2	4
452	Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/ μ l. <i>Aids</i> , 2002, 16, 1551-1554.	2.2	17
453	High incidence of tuberculin skin test conversion among HIV-infected individuals who have a favourable immunological response to highly active antiretroviral therapy. <i>Aids</i> , 2002, 16, 1976-1979.	2.2	25
454	A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients. <i>Antiviral Therapy</i> , 2002, 7, 123-129.	1.0	122
455	Plasma levels of interleukin-6 and interleukin-10 in preterm neonates evaluated for sepsis. <i>European Journal of Pediatrics</i> , 2001, 160, 345-350.	2.7	110
456	HIV Infection Among Foreign Transsexual Sex Workers in Rome. <i>Sexually Transmitted Diseases</i> , 2001, 28, 405-411.	1.7	35
457	Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. <i>Aids</i> , 2001, 15, 1483-1491.	2.2	175
458	When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. <i>Aids</i> , 2001, 15, 983-990.	2.2	87
459	Adherence to Protease Inhibitors. <i>Annals of Internal Medicine</i> , 2001, 134, 625.	3.9	2
460	Incidence and Determinants of Bacterial Infections in HIV-Positive Patients Receiving Anti-Pneumocystis carinii/ Toxoplasma gondii Primary Prophylaxis Within a Randomized Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 49-55.	2.1	2
461	Changing Clinical Presentation and Survival in HIV-Associated Tuberculosis After Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 326-331.	2.1	22
462	Changes in Neurocognitive Performance in a Cohort of Patients Treated With HAART for 3 Years. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 19-27.	2.1	74
463	Incidence and Determinants of Bacterial Infections in HIV-Positive Patients Receiving Anti-Pneumocystis carinii/ Toxoplasma gondii Primary Prophylaxis Within a Randomized Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 49-55.	2.1	4
464	Human immunodeficiency virus-related non-Hodgkin lymphoma. <i>Cancer</i> , 2001, 92, 200-206.	4.1	27
465	Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. <i>Journal of NeuroVirology</i> , 2001, 7, 323-328.	2.1	68
466	Potent anti-retroviral therapy with or without didanosine for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. <i>Journal of NeuroVirology</i> , 2001, 7, 364-368.	2.1	64
467	Self-Reported Nonadherence with Antiretroviral Drugs Predicts Persistent Condition. <i>HIV Clinical Trials</i> , 2001, 2, 323-329.	2.0	31
468	Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 28, 114-123.	2.1	79

#	ARTICLE	IF	CITATIONS
469	Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 445-449.	2.1	405
470	Sexual behaviour of heterosexual individuals with HIV infection naive for antiretroviral therapy in Italy. <i>Sexually Transmitted Infections</i> , 2001, 77, 130-134.	1.9	9
471	Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. <i>Aids</i> , 2001, 15, 1579-1581.	2.2	67
472	Acute hepatitis B by sexual transmission after interruption of lamivudine-containing antiretroviral regimen. <i>Aids</i> , 2001, 15, 2062-2063.	2.2	3
473	Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy. <i>Aids</i> , 2001, 15, 2325-2327.	2.2	20
474	Sexual Transmission of Transfusion-Transmitted Virus. <i>Sexually Transmitted Diseases</i> , 2001, 28, 298-299.	1.7	1
475	Community-Acquired <i>Acinetobacter baumannii</i> Bacteremia in an HIV-Positive Patient. <i>Emerging Infectious Diseases</i> , 2001, 7, 1032-1035.	4.3	23
476	Changes in Neurocognitive Performance in a Cohort of Patients Treated With HAART for 3 Years. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 28, 19-27.	2.1	1
477	Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. <i>Neurology</i> , 2000, 54, 993-997.	1.1	42
478	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 123-128.	2.1	65
479	Epstein-Barr Virus Infection Is Predictive of CNS Involvement in Systemic AIDS-Related Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2000, 18, 3325-3330.	1.6	92
480	Circulating Levels and <i>In Vivo</i> Production of β -Chemokines, Interferon β , and Interleukin 2 in Advanced Human Immunodeficiency Virus Type 1 Infection: The Effect of Protease Inhibitor Therapy. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 835-843.	1.1	12
481	AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. <i>Neurology</i> , 2000, 55, 1194-1200.	1.1	111
482	Brief Report: Disseminated Mycobacteriosis Caused by Drug-Resistant <i>Mycobacterium triplex</i> in a Human Immunodeficiency Virus-Infected Patient during Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2000, 31, 177-179.	5.8	25
483	Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral-naïve patients. <i>Aids</i> , 2000, 14, 499-507.	2.2	483
484	Patient-Reported Nonadherence to HAART Is Related to Protease Inhibitor Levels. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 123-128.	2.1	120
485	Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. <i>Aids</i> , 2000, 14, F117-F121.	2.2	72
486	The Effect of Potent Antiretroviral Therapy and JC Virus Load in Cerebrospinal Fluid on Clinical Outcome of Patients with AIDS-Associated Progressive Multifocal Leukoencephalopathy. <i>Journal of Infectious Diseases</i> , 2000, 182, 1077-1083.	4.0	113

#	ARTICLE	IF	CITATIONS
487	Discontinuation of Primary Prophylaxis for Pneumocystis carinii Pneumonia and Toxoplasmic Encephalitis in Human Immunodeficiency Virus Type 1-Infected Patients: The Changes in Opportunistic Prophylaxis Study. <i>Journal of Infectious Diseases</i> , 2000, 181, 1635-1642.	4.0	103
488	Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. <i>Aids</i> , 2000, 14, 1655-1656.	2.2	11
489	Clinical and Virological Monitoring During Treatment with Intrathecal Cytarabine in Patients with AIDS-Associated Progressive Multifocal Leukoencephalopathy. <i>Clinical Infectious Diseases</i> , 1999, 28, 624-628.	5.8	55
490	Use of Antiretroviral Therapy by Intravenous Drug Users With HIV. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 699.	7.4	12
491	Mutations in Genes Associated with Drug Resistance in <i>Mycobacterium tuberculosis</i> Isolates from Italy. <i>Journal of Infectious Diseases</i> , 1999, 180, 1751-1752.	4.0	4
492	Application of Molecular Methods for Detection and Transmission Analysis of <i>Mycobacterium tuberculosis</i> Drug Resistance in Patients Attending a Reference Hospital in Italy. <i>Journal of Infectious Diseases</i> , 1999, 179, 1025-1029.	4.0	18
493	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. <i>Annals of Neurology</i> , 1999, 45, 259-261.	5.3	37
494	Definition and measurement of adherence to antiretroviral drugs in HIV-1-infected patients. <i>Lancet</i> , 1999, 353, 1974.	13.7	16
495	HHV-8/KSHV is Not Associated with AIDS-Related Primary Central Nervous System Lymphoma. <i>Brain Pathology</i> , 1999, 9, 199-208.	4.1	26
496	Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. <i>European Journal of Haematology</i> , 1999, 63, 77-85.	2.2	71
497	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. <i>Annals of Neurology</i> , 1999, 45, 259-261.	5.3	1
498	AIDS-Associated Kaposi's Sarcoma Is More Aggressive in Women: A Study of 54 Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 20, 337-341.	0.3	24
499	Response to zidovudine after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy. <i>Neurology</i> , 1999, 52, 891-891.	1.1	47
500	Minimally Invasive Diagnosis of Acquired Immunodeficiency Syndrome-Related Primary Central Nervous System Lymphoma. <i>Journal of the National Cancer Institute</i> , 1998, 90, 364-369.	6.3	117
501	Evaluation and management of intracranial mass lesions in AIDS: Report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 1998, 51, 1233-1233.	1.1	11
502	Defining and Measuring Quality of Life in Medicine. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 429.	7.4	17
503	Changing Disease Patterns in Focal Brain Lesion-Causing Disorders in AIDS. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 365-371.	0.3	46
504	Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. <i>Aids</i> , 1998, 12, 473-480.	2.2	35

#	ARTICLE	IF	CITATIONS
505	Antiretroviral Therapy and Improving AIDS Survival. JAMA - Journal of the American Medical Association, 1998, 279, 1874-1875.	7.4	3
506	Analysis of Human Herpesvirus Type 8 Infection in AIDS-Related and AIDS-Unrelated Primary Central Nervous System Lymphoma. Journal of Infectious Diseases, 1997, 175, 1193-1197.	4.0	31
507	Diagnosis of AIDS-related focal brain lesions. Neurology, 1997, 48, 687-694.	1.1	214
508	Disease-Related Factors Associated With Health-Related Quality of Life in People With Nonadvanced HIV Disease Assessed Using an Italian Version of the MOS-HIV Health Survey. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 350-356.	0.3	45
509	Immunological Aspects of Patients with HIV-1 Disease following Immunization with Recombinant gp160 (VaxSyn). Antibiotics and Chemotherapy, 1996, 48, 147-154.	0.5	4
510	Low-dose dapsone, co-trimoxazole, and survival in Pneumocystis carinii primary prophylaxis. Aids, 1996, 10, 1046-1047.	2.2	1
511	Cognitive Impairment in Asymptomatic Stages of HIV Infection. European Neurology, 1996, 36, 125-133.	1.4	35
512	Combination chemotherapy with doxorubicin, bleomycin, and vindesine for AIDS-related Kaposi's sarcoma. , 1996, 77, 2117-2122.		11
513	Fatal Toxic Epidermolysis Induced by Zidovudine. Clinical Infectious Diseases, 1996, 23, 640-641.	5.8	38
514	PCR detection of Toxoplasma gondii DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. Journal of Medical Microbiology, 1996, 45, 472-476.	1.8	72
515	Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis. Journal of Medical Microbiology, 1996, 45, 146-148.	1.8	16
516	Karnofsky Performance Status and Assessment of Global Health Status. Journal of Acquired Immune Deficiency Syndromes, 1996, 13, 294.	0.3	18
517	Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Aids, 1995, 9, 1343-1350.	2.2	62
518	Evaluation of cerebrospinal fluid EBV DNA and IL-10 as markers for <i>in vivo</i> diagnosis of AIDS-related primary central nervous system lymphoma. British Journal of Haematology, 1995, 90, 844-849.	2.5	121
519	Epidemic HIV-related Kaposi's sarcoma: A retrospective analysis and validation of TIS staging. Annals of Oncology, 1995, 6, 383-387.	1.2	10
520	Role of <i>Pneumocystis carinii</i> DNA Amplification by PCR on the Diagnosis of <i>Pneumocystis carinii</i> Pneumonia in Patients with Haematologic Malignant Diseases: Report of Four Cases. Acta Haematologica, 1995, 94, 163-166.	1.4	3
521	Fluconazole for Primary Prophylaxis of AIDS-associated Cryptococcosis: A Case-control Study. Scandinavian Journal of Infectious Diseases, 1995, 27, 235-237.	1.5	14
522	Morganella morganii Pericarditis After Resolvent Splenectomy for Immune Pancytopenia Following Allogeneic Bone Marrow Transplantation for Acute Lymphoblastic Leukemia. Clinical Infectious Diseases, 1995, 21, 1052-1053.	5.8	19

#	ARTICLE	IF	CITATIONS
523	Presumptive Clinical Criteria Versus Endoscopy in the Diagnosis of Candida Esophagitis at Various HIV-1 Disease Stages. <i>Endoscopy</i> , 1995, 27, 371-376.	1.8	14
524	Variable efficiency of three primer pairs for the diagnosis of <i>Pneumocystis carinii</i> pneumonia by the polymerase chain reaction. <i>Molecular and Cellular Probes</i> , 1995, 9, 333-340.	2.1	23
525	Prognostic factors of early fatal outcome and long-term survival in patients with <i>Pneumocystis carinii</i> pneumonia and acquired immunodeficiency syndrome. <i>European Journal of Epidemiology</i> , 1993, 9, 183-189.	5.7	16
526	Haemopoietic CD34+ progenitor cells are not infected by HIV-1 in vivo but show impaired clonogenesis. <i>British Journal of Haematology</i> , 1993, 85, 20-24.	2.5	74
527	Primary central nervous system lymphoma and brain biopsy in AIDS. <i>Lancet, The</i> , 1993, 341, 1411-1412.	13.7	15
528	Neuropsychological abnormalities in AIDS and asymptomatic HIV seropositive patients.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 878-884.	1.9	25
529	Diagnosis of <i>Pneumocystis carinii</i> pneumonia: Specificity and sensitivity of polymerase chain reaction in comparison with immunofluorescence in bronchoalveolar lavage specimens. <i>Journal of Medical Microbiology</i> , 1993, 38, 449-453.	1.8	57
530	Cardiac Surgery in HIV-positive Intravenous Drug Addicts: Influence of Cardiopulmonary Bypass on the Progression to AIDS. <i>Thoracic and Cardiovascular Surgeon</i> , 1992, 40, 279-282.	1.0	27
531	Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of <i>Pneumocystis carinii</i> pneumonia. <i>Lancet, The</i> , 1992, 340, 788.	13.7	18
532	Evaluation of different staging systems for Kaposi's sarcoma in HIV-infected patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 118, 635-636.	2.5	10
533	Comparison of two medications in central nervous system toxoplasmosis in patients with AIDS. <i>Italian Journal of Neurological Sciences</i> , 1992, 13, 475-479.	0.1	7
534	Premenopausal cytomegalovirus oophoritis in a patient with AIDS. <i>Aids</i> , 1991, 5, 458.	2.2	13
535	Influence of two antimalarials, chloroquine and mefloquine, on human myelopoiesis in vitro. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1991, 85, 42-43.	1.8	3
536	Prevalence of anti-HCV antibodies in Cameroon. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1991, 85, 654-655.	1.8	15
537	<i>Pneumocystis carinii</i> stimulates in vitro production of tumor necrosis factor- α by human macrophages. <i>Medical Microbiology and Immunology</i> , 1991, 180, 15-20.	4.8	34
538	Lipoprotein 90K in Human Immunodeficiency Virus-Infected Patients: A Further Serologic Marker of Progression. <i>Journal of Infectious Diseases</i> , 1991, 164, 819-819.	4.0	26
539	Epidemiological and clinical aspects of mycoses in patients with aids-related pathologies. <i>European Journal of Epidemiology</i> , 1990, 6, 398-403.	5.7	17
540	Influence of two quinolones, ofloxacin and pefloxacin, on human myelopoiesis in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 1989, 33, 122-123.	3.2	11

#	ARTICLE	IF	CITATIONS
541	Neurological features in AIDS patients: Studies on cerebrospinal fluid. Italian Journal of Neurological Sciences, 1988, 9, 567-572.	0.1	2
542	Influence of ofloxacin and pefloxacin on human lymphocyte immunoglobulin secretion and on polymorphonuclear leucocyte superoxide anion production. Journal of Antimicrobial Chemotherapy, 1988, 22, 193-196.	3.0	67
543	A Study on the Incidence of Postoperative Infections and Surgical Sepsis in a University Hospital. Infection Control, 1987, 8, 320-324.	0.1	16
544	Evaluation of epidemiological and economic consequences due to the delay in treatment of hiv-positive patients caused by the covid-19 pandemic. Global & Regional Health Technology Assessment, 0, 8, 147-154.	0.1	0